Clinical Trials Directory

Trials / Conditions / Recurrent Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis

14 registered clinical trials studyying Recurrent Langerhans Cell Histiocytosis — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingQ702 for the Treatment of Patients With Hematologic Malignancies
NCT06712810
Mayo ClinicPhase 1
RecruitingA Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Ce
NCT05828069
National Cancer Institute (NCI)Phase 2
Active Not RecruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating
NCT04320888
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter
NCT04284774
National Cancer Institute (NCI)Phase 2
Active Not RecruitingIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat
NCT04195555
National Cancer Institute (NCI)Phase 2
Active Not RecruitingUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi
NCT03698994
National Cancer Institute (NCI)Phase 2
CompletedPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly
NCT03526250
National Cancer Institute (NCI)Phase 2
Active Not RecruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H
NCT03210714
National Cancer Institute (NCI)Phase 2
Active Not RecruitingEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi
NCT03213652
National Cancer Institute (NCI)Phase 2
CompletedSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H
NCT03213678
National Cancer Institute (NCI)Phase 2
CompletedTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213665
National Cancer Institute (NCI)Phase 2
CompletedOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist
NCT03233204
National Cancer Institute (NCI)Phase 2
Active Not RecruitingLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213704
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc
NCT03155620
National Cancer Institute (NCI)Phase 2